Loading
A phase 3 trial of Dacomitinib and Erlotinib in Non-small-cell lung cancer, run by Pfizer, completed.
ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT01360554 by Pfizer, with 878 participants recorded, started 2011-06-16 and reaching its primary completion in 2013-09-30. Interventions recorded: Dacomitinib (PF-00299804), Active Comparator (erlotinib), Placebo erlotinib, Placebo PF00299804. Conditions recorded: Non-Small Cell Lung Cancer.
Linked to the drug Dacomitinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
878 enrolled.
95% CI 1.9 to 2.8; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication · 95% CI 1.9 to 2.8
Source95% CI 1.9 to 2.9; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication · 95% CI 1.9 to 3.0
Source95% CI 6.8 to 9.0; Figures from the ClinicalTrials.gov results section (first posted 2017-05-24), not from a publication · 95% CI 7.4 to 9.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Per Independent Radiologic Review.primary | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 439 | 2.6 months | 0.933 (0.797 to 1.093) | 0.195 | link |
| Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 439 | 2.5 months | ||||
| Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.primary | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 256 | 2.6 months | 1.037 (0.848 to 1.268) | 0.643 | link |
| Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 263 | 2.5 months | ||||
| Overall Survival (OS). | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 439 | 7.9 months | 1.026 (0.887 to 1.188) | 0.638 | link |
| Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 439 | 8.3 months |
Shares Dacomitinib, Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen) and the tag pipeline.